About Dr. Grunberger
About Dr. Grunberger
Dr. George Grunberger, received his B.A. (biochemistry) from Columbia College of Columbia University (New York City), M.D. from New York University School of Medicine (New York City), internal medicine training at Case Western Reserve University in Cleveland, Ohio and Endocrinology/Metabolism training in the Diabetes Branch at the National Institutes of Health in Bethesda, Maryland where he then stayed as senior investigator.
Between 1986 and 2002 he established and then directed the Comprehensive Diabetes Programs at both the Detroit Medical Center and Wayne State University School of Medicine. Early in his career, Dr. Grunberger saw the need for a comprehensive diabetes treatment facility where persons with diabetes could receive specialized care and address the many facets of their disease. The Grunberger Diabetes Institute, established in 2002, is the result of his vision.
Grunberger Diabetes Institute (GDI) is unique in the Metro Detroit area for uniting a multidisciplinary approach to sophisticated diabetes and endocrine management and education with an offer to participate in the clinical diabetes research studies – all under one roof – with the same team of experienced professionals. We strive to be the best: to provide specialized medical treatment in a highly professional, intimate, and caring manner. Our focus is on keeping you, your family, and your referring physicians well-informed and satisfied.
Dr. Grunberger is Accredited with
Recent Articles Co-Authored by Dr. Grunberger
American Association of Clinical Endocrinology Clinical Practice Guideline: The use of advanced technology in the management of persons with diabetes mellitus. Endocr Pract 27: 505-537, 2021
Beyond A1c Writing Group: Need for regulatory change to incorporate beyond A1c glycemic metrics. Diabetes Care 41(6): e92-e94, 2018.
Dysglycemia-based chronic disease: An American Association of Clinical Endocrinologists position statement. Endocr Pract 24: 995-1011, 2018.
C-peptide and beta-cell autoantibody testing prior to initiating continuous subcutaneous insulin infusion pump therapy did not improve utilization or medical costs among older adults with diabetes mellitus. Endocr Pract 24: 634-645, 2018.
Glucose management indicator (GMI): A new term for estimating A1C from continuous glucose monitoring. Diabetes Care 41: 2275-2280, 2018.
Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm – 2019 Executive Summary. Endocr Pract 25: 69-100, 2019.
International Consensus on Risk Management of Diabetic Ketoacidosis in Patients with Type 1 Diabetes Treated with Sodium-Glucose Cotransporter (SGLT) Inhibitors. Diabetes Care 42: 1147-1154, 2019.
Clinical targets for continuous glucose monitoring data interpretation: Recommendations from the International Consensus on Time in Range. Diabetes Care 42: 1593-1603, 2019.
Effectiveness of V-Go for patients with type 2 diabetes in a real-world setting: A prospective observational study. Drugs – Real World Outcomes doi.org/10.1007/s40801-019-00173-8, 2019.
Human Regular U-500 insulin via continuous subcutaneous infusion vs. multiple daily injections in adults with type 2 diabetes: the VIVID study. Diab Obes Metab 22: 434-441, 2020.
Glycemic outcomes in adults with T1D are impacted more by continuous glucose monitoring than by insulin delivery method: 3 years of follow-up from the COMISAIR study. Diabetes Care 43: 37-43, 2020.
Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm – 2020 Executive Summary. Endocr Pract 26: 107-139, 2020.
Treatment intensification with insulin pumps and other technologies in patients with type 2 diabetes: Results of a physician survey in the United States. Clin Diabetes 38: 47-55, 2020.
Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the management of dyslipidemia and prevention of cardiovascular disease algorithm – 2020 Executive Summary. Endocr Pract 26: 1196-1224, 2020.
Real-time CGM is superior to flash glucose monitoring for glucose control in type 1 diabetes: The CORRIDA randomized control trial. Diabetes Care 43: 2744-2750, 2020.